Idera Pharmaceuticals EBITDA 2011-2026 | IDRA

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Idera Pharmaceuticals

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-27.7 M	-27.6 M	-36.6 M	-45.8 M	-56.2 M	-65.7 M	-38.1 M	-48.4 M	-38.5 M	-18 M	-19.6 M	-25.4 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-18 M	-65.7 M	-37.3 M

Quarterly EBITDA Idera Pharmaceuticals

2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-20.6 M	-	-9.32 M	-5.36 M	-4.18 M	-	-5.95 M	-7.55 M	-9.93 M	-	-7.43 M	-7.97 M	-13.1 M	-	-11.3 M	-11.4 M	-11.3 M	-	-11.8 M	-16.2 M	-20.1 M	-	-14.5 M	-21.4 M	-15 M	-	-12.8 M	-13.4 M	-12.7 M	-	-11.3 M	-12.7 M	-12.4 M	-	-9.46 M	-8.28 M	-8.94 M	-	-4.65 M	-3.53 M	-3.81 M	-	-4.7 M	-5.26 M	-5.41 M	-	-5.4 M	-6.15 M	-6.7 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-3.53 M	-21.4 M	-10.1 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
BioLineRx Ltd. BLRX	-24.8 M	$ 2.25	1.81 %	$ 908 M	Israel
BioNTech SE BNTX	15.3 B	$ 91.28	0.11 %	$ 27.2 B	Germany
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
Alnylam Pharmaceuticals ALNY	557 M	$ 330.34	3.6 %	$ 43.3 B	USA
CollPlant Biotechnologies Ltd. CLGN	-16.2 M	$ 0.44	-16.64 %	$ 5.04 M	Israel
I-Mab IMAB	13.8 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	31.8 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Catalyst Pharmaceuticals CPRX	258 M	$ 24.98	1.17 %	$ 3.05 B	USA
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
Corbus Pharmaceuticals Holdings CRBP	-85.1 M	$ 10.14	-0.29 %	$ 135 M	USA
Cardiff Oncology CRDF	-48.6 M	$ 1.58	-	$ 106 M	USA
Curis CRIS	-5.54 M	$ 0.53	-3.07 %	$ 6.98 M	USA
Acorda Therapeutics ACOR	-233 M	-	-24.86 %	$ 820 K	USA
Crinetics Pharmaceuticals CRNX	-513 M	$ 37.7	1.26 %	$ 3.55 B	USA
CRISPR Therapeutics AG CRSP	-645 M	$ 49.15	-0.73 %	$ 4.42 B	Schweiz
Adverum Biotechnologies ADVM	-136 M	-	-	$ 86.2 M	USA
Advaxis ADXS	-35.9 M	-	-9.65 %	$ 45.9 M	USA
Anavex Life Sciences Corp. AVXL	-51.4 M	$ 2.96	-1.0 %	$ 252 M	USA
Applied Molecular Transport AMTI	-124 M	-	-	$ 10.1 M	USA
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-23.9 M	-	-10.17 %	$ 12.2 K	USA
AIkido Pharma AIKI	-55.6 M	-	1.93 %	$ 17.4 M	USA
Aeglea BioTherapeutics AGLE	-242 M	-	-	$ 1.01 B	USA
CytomX Therapeutics CTMX	-21.2 M	$ 4.4	-3.51 %	$ 607 M	USA
Applied Genetic Technologies Corporation AGTC	-16.2 M	-	-	$ 26.5 M	USA
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
Akouos AKUS	-84.3 M	-	0.23 %	$ 488 M	USA
Институт стволовых клеток человека ISKJ	220 M	-	-	-	Russia
Citius Pharmaceuticals CTXR	-42 M	$ 0.86	0.67 %	$ 5.79 M	USA
Cue Biopharma CUE	-25.6 M	$ 0.18	-1.61 %	$ 17.1 M	USA
Allena Pharmaceuticals ALNA	-47.3 M	-	3.16 %	$ 1.9 M	USA
Alpine Immune Sciences ALPN	-57.6 M	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	-50.6 M	-	10.36 %	$ 9.8 M	USA
Aquestive Therapeutics AQST	-70.5 M	$ 4.09	-0.97 %	$ 437 M	USA
Cyclerion Therapeutics CYCN	-3.63 M	$ 4.15	-32.52 %	$ 10.4 M	USA
Daré Bioscience DARE	-11.9 M	$ 1.81	4.02 %	$ 20.2 M	USA
DBV Technologies S.A. DBVT	-144 M	$ 20.36	-3.32 %	$ 2.84 B	France
Aravive ARAV	-70 M	-	-13.39 %	$ 1.45 M	USA
Arcturus Therapeutics Holdings ARCT	-73.2 M	$ 8.22	2.37 %	$ 225 M	Israel
Aptose Biosciences APTO	22 K	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	-62.4 M	-	-39.0 %	$ 4.57 M	USA
Denali Therapeutics DNLI	-480 M	$ 19.38	-6.15 %	$ 3.19 B	USA
Dyadic International DYAI	-7.19 M	$ 0.87	-2.8 %	$ 31.5 M	USA
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
AstraZeneca PLC AZN	1.06 B	-	-	$ 96.9 B	Britain
Celldex Therapeutics CLDX	-284 M	$ 31.37	1.0 %	$ 2.08 B	USA
Avenue Therapeutics ATXI	-3.08 M	-	-52.27 %	$ 4.45 M	USA